English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We appreciate the insightful commentary by Drs. Choi and Simone regarding the phase II study of concurrent chemotherapy and dose-escalated proton beam therapy (PBT) for locally advanced non-resected non-small cell lung cancer (NSCLC) (1). We wish to add several discussion points that are in concord with the aforementioned piece.

Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy